Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Department of Pharmacy, Hokkaido University Hospital, Sapporo, Japan.
Anticancer Res. 2020 Mar;40(3):1747-1751. doi: 10.21873/anticanres.14128.
BACKGROUND/AIM: Previous reports have demonstrated that non-steroidal anti-inflammatory drugs (NSAIDs) are a risk factor for cisplatin-induced nephrotoxicity (CIN). Here, the results of these previous studies were comprehensively assessed via a meta-analysis.
After a database search to select eligible studies, a meta-analysis was performed using a forest plot, followed by an assessment of the heterogeneity and publication bias and a subgroup analysis.
Seven studies were extracted as candidates. All were retrospective studies and evaluated the effect of NSAIDs on CIN as a secondary endpoint. According to the meta-analysis, total odds ratio was 1.88 (95% confidence interval=1.44-2.45). Further, high heterogeneity and publication bias were not observed. A subgroup analysis of the chemotherapy evaluation period revealed that CIN tended to be enhanced in the first course group (evaluation in only 1 course) and was significantly enhanced in the total course group (evaluation in 1 or more courses) by NSAIDs co-administration.
NSAIDs co-administration could be a risk factor for CIN.
背景/目的：既往研究表明，非甾体类抗炎药（NSAIDs）是顺铂诱导肾毒性（CIN）的一个危险因素。在此，通过荟萃分析综合评估了这些既往研究的结果。
在数据库检索以选择合格的研究后，通过森林图进行荟萃分析，然后评估异质性和发表偏倚，并进行亚组分析。
提取了 7 项研究作为候选研究。所有研究均为回顾性研究，将 NSAIDs 对 CIN 的影响作为次要终点进行评估。根据荟萃分析，总优势比为 1.88（95%置信区间=1.44-2.45）。此外，未观察到高度异质性和发表偏倚。化疗评估期的亚组分析表明，CIN 似乎在第一疗程组（仅评估 1 个疗程）中加重，且在 NSAIDs 联合治疗的总疗程组（评估 1 个或更多疗程）中显著加重。
NSAIDs 联合治疗可能是 CIN 的一个危险因素。
